



Financial Tear Sheet

CORPORATE PROFILE

Motif Bio is a clinical stage biopharmaceutical company which specializes in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings. Motif is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram positive and Gram negative bacteria.

PRIMARY IR CONTACT

E-mail: ir@motifbio.com

STOCK DETAILS

| MTFB (ADS) | |
|---------------------------|-----------------------|
| Exchange | NASDAQ GS (US Dollar) |
| Price | \$10.88 |
| Change (%) | ▲ 0.15 (1.40%) |
| Volume | 3,150 |
| 52 Week Low | \$5.15 |
| Market Cap | \$ |
| Rolling EPS | 0.00 |
| PE Ratio | 0 |
| Shares Outstanding | |

Data as of October 20, 2017 10:52 a.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.



RECENT NEWS & UPCOMING EVENTS

October 6, 2017

There are currently no events scheduled.

Motif Bio Presents New Pre-Clinical Data for Iclaprim at

IDWeek 2017™

October 4, 2017

Motif Bio Announces Positive Topline Results for iclaprim in

the REVIVE-2 Phase 3 Study

September 29, 2017

Motif Bio reports half-year 2017 financial results and

operational progress

SEC FILINGS

| Filing Date | Form |
|--------------------|-------------|
| October 6, 2017 | 6-K |
| October 4, 2017 | 6-K |
| September 29, 2017 | 6-K |
| September 25, 2017 | 6-K |